VAXIL BIO LTD (VXL.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:VXL - CA92243L2066 - Common Stock
VXL.CA Key Statistics, Chart & Performance
The current stock price of VXL.CA is 0.145 CAD. In the past month the price decreased by -23.68%. In the past year, price increased by 866.67%.
VXL.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 522.71M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 416.39M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 181.02M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 76.74M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.86 | 48.06M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 31.97M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.73M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.42M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.96M | ||
| MPH.CA | MEDICURE INC | N/A | 11.90M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.03M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M |
Related stock screener links
About VXL.CA
Company Profile
Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The company has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The company exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Company Info
VAXIL BIO LTD
559 Briar Hill Avenue,
TORONTO ONTARIO M5X 1A4 CA
CEO: David Goren
Employees: 0
VAXIL BIO LTD / VXL.CA FAQ
What does VAXIL BIO LTD do?
Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The firm also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. The company has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. The company exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
What is the current price of VXL stock?
The current stock price of VXL.CA is 0.145 CAD. The price increased by 3.57% in the last trading session.
Does VAXIL BIO LTD pay dividends?
VXL.CA does not pay a dividend.
What is the ChartMill rating of VAXIL BIO LTD stock?
VXL.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy VXL stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VXL.CA.
What is the ownership structure of VAXIL BIO LTD (VXL.CA)?
You can find the ownership structure of VAXIL BIO LTD (VXL.CA) on the Ownership tab.
VXL.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to VXL.CA. When comparing the yearly performance of all stocks, VXL.CA is one of the better performing stocks in the market, outperforming 98.84% of all stocks.
VXL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VXL.CA. No worries on liquidiy or solvency for VXL.CA as it has an excellent financial health rating, but there are worries on the profitability.
VXL.CA Financial Highlights
Over the last trailing twelve months VXL.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 22.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.37% | ||
| ROE | -10.49% | ||
| Debt/Equity | 0 |